Daphne Karydas Sells Shares of Mineralys Therapeutics

Daphne Karydas recently sold 3,000 shares of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) in a planned transaction on June 17, 2026. The shares were sold at an average price of $25.00, totaling $75,000.

Insider Buying and Selling at Mineralys Therapeutics, Inc.

Daphne Karydas executed a planned sale of 3,000 shares valued at $75,000 on June 17, 2026. This transaction was part of a pre-arranged trading plan. On the same day, Chief Medical Officer David Malcom Rodman also sold 4,584 shares at $25.00 each in a planned transaction.

Other Institutional Activity in Mineralys Therapeutics

Several institutional investors have adjusted their positions in Mineralys Therapeutics. RA Capital Management, L.P. increased its holdings by 369,000 shares, bringing its total to 7,692,750 shares valued at approximately $208.4 million. BlackRock, Inc. added 153,904 shares, resulting in a total of 4,481,582 shares worth about $121.4 million. In contrast, FMR LLC reduced its stake by 196,405 shares, ending with 4,861,104 shares valued at $131.7 million.

Mineralys Therapeutics Stock Snapshot

Shares of Mineralys Therapeutics (NasdaqGS: MLYS) traded near $23.99. The company has a market capitalization of approximately $2.11 billion. With no meaningful P/E ratio due to lack of profitability, the stock has a beta of 0.565. Its 52-week low is $12.59, and its high is $47.65. The 50-day moving average is $27.72, while the 200-day moving average is $33.07. The company's current ratio is a strong 44.33, indicating solid liquidity.

Analysts Set New Price Targets

Analysts remain optimistic about Mineralys Therapeutics, with B of A Securities maintaining a 'buy' rating and a $51.00 price target as of March 13, 2026. The consensus among eight analysts is a 'strong buy' rating, with an average price target of $49.00.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc. is a biopharmaceutical company based in Radnor, Pennsylvania. It focuses on developing treatments for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is aimed at treating conditions like hypertension and chronic kidney disease. The company, led by CEO Dr. Jon Congleton, employs 76 people.

Bottom Line

Daphne Karydas's recent sale of shares in Mineralys Therapeutics is part of a planned trading strategy. Investors often monitor insider transactions for insights, though these sales don't necessarily reflect a lack of confidence. The company remains a point of interest, with analysts maintaining strong buy ratings and setting ambitious price targets.